0103, 2021

Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month

View Press Release Bordentown, NJ – March 1, 2021 – Caelum Biosciences, Inc. (“Caelum”), a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases, today announced its collaboration with and support of the amyloidosis advocacy community as Amyloidosis Awareness Month begins. The campaign was created to spread awareness about this rare disease and its symptoms to help prompt earlier diagnosis for patients. In honor of the month and

0411, 2020

Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition

– – Accepted abstracts include Phase 2 safety, efficacy, and tolerability data for CAEL-101 in AL amyloidosis – – Phase 3 studies of CAEL-101 in AL amyloidosis are underway – BORDENTOWN, N.J. & BOSTON – November 04, 2020 11:55 AM Eastern Standard Time – (BUSINESS WIRE)–Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a first-in-class amyloid fibril targeted therapy, have been accepted for presentation at the

1409, 2020

Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

– Positive long-term Phase 1a/1b data presented at the International Symposium on Amyloidosis (ISA) 2020 demonstrate prolonged overall survival (78% at 37 months) and durable organ response – – Phase 2 study met primary objective, supporting initiation of two parallel Phase 3 studies that will enroll ~370 AL amyloidosis patients – BOSTON & BORDENTOWN, N.J. – SEPTEMBER 14, 2020 – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Caelum Biosciences today announced the initiation of the Cardiac Amyloid

0212, 2019

Caelum Biosciences Granted Orphan Medicinal Product Designation from the European Commission for CAEL-101 for the Treatment of AL Amyloidosis

BORDENTOWN, NJ – December 2, 2019 – Caelum Biosciences, Inc. (“Caelum”), a company focused on developing treatments for rare and life-threatening diseases, today announced that the European Commission (EC) has granted orphan medicinal product designation to CAEL-101 (previously known as 11-1F4), a light chain fibril-reactive monoclonal antibody (“mAb”), for the treatment of amyloid light chain (“AL”) amyloidosis. CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by

3101, 2019

Alexion and Caelum Biosciences Announce Collaboration to Develop Targeted Therapy for Light Chain (AL) Amyloidosis

View Release – Collaboration provides opportunity to diversify Alexion’s clinical-stage rare hematology portfolio – – Caelum to receive up to $60 million for equity investment and option fee – – Alexion has option to acquire Caelum based on Phase 2 data – January 31, 2019 06:30 AM Eastern Standard Time BOSTON & NEW YORK–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Caelum Biosciences today announced a collaboration to develop CAEL-101 for light

0412, 2018

Caelum Biosciences Announces Two Oral Presentations of Additional Data from Phase 1b Study of Anti-Amyloid mAb CAEL-101 and Preclinical Imaging Study at 60th American Society of Hematology Annual Meeting

View Press Release Phase 1b data confirm efficacy in AL Amyloidosis with two cardiac markers correlated with survival Preclinical data demonstrate the potential of using radiolabeled CAEL-101 for real-time imaging of human amyloidosis in vivo NEW YORK, NY – December 4, 2018 – Caelum Biosciences, Inc. (“Caelum”), a company focused on developing treatments for rare and life-threatening diseases, today announced additional global longitudinal strain (“GLS”) data from the Phase 1b study of

0211, 2018

Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentations at 60th American Society of Hematology Annual Meeting

View Press Release NEW YORK, NY – November 2, 2018 – Caelum Biosciences, Inc. (“Caelum”), a company focused on developing treatments for rare and life-threatening diseases, today announced that additional global longitudinal strain (“GLS”) data from the Phase 1b study of CAEL-101 (a light chain fibril-reactive monoclonal antibody 11-1F4) in patients with amyloid light chain (“AL”) amyloidosis and imaging data from a pre-clinical study have been selected for two oral presentations

2506, 2018

Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis

View Press Release Nine of 10 cardiac patients on CAEL-101 showed improvement in global longitudinal strain CAEL-101 led to sustained decrease in NT-proBNP levels Data presented at American Society of Echocardiography 29th Annual Scientific Sessions NEW YORK, NY – June 25, 2018 – Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ: FBIO) Company developing treatments for rare and life-threatening diseases, today announced a complete analysis of cardiac data from

1806, 2018

Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions

View Press Release Columbia University to present data demonstrating CAEL-101 positively impacts myocardial function in patients with AL amyloidosis as measured by global longitudinal strain NEW YORK, NY – June 18, 2018 – Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ: FBIO) Company developing treatments for rare and life-threatening diseases, today announced that Columbia University (“Columbia”) will present a complete analysis of cardiac data from the Phase 1b trial

2004, 2018

Caelum Biosciences Submits Draft Registration Statement on Form S-1 to the Securities and Exchange Commission

View Press Release NEW YORK, NY – April 20, 2018 – Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. Company developing treatments for rare and life-threatening diseases, today announced it has confidentially submitted a draft registration statement on Form S-1 to the Securities and Exchange Commission (the “SEC”) related to its proposed initial public offering. The number of shares of stock and the price range for the proposed offering have